SpectraScience has announced that it has filed for a new patent with the United States Patent and Trademark Office. The application is titled "System and Method for Non-Endoscopic Optica
NanoMed Pharmaceuticals has announced that founders Russell J. Mumper, Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525 entitled "Microemulsions As Precursors To Solid Nanoparti
Applied Digital Solutions, though its subsidiary VeriChip Corporation has announced today that the U.S. Patent and Trademark Office has granted VeriChip Corp. a patent for its portable RFID asset
MedImmune issued the following statement regarding today's U.S. Supreme Court decision in MedImmune, Inc. vs. Genentech, Inc. et al.: By granting MedImmune's appeal, the U.S. Supr
Ryogen LLC announced today that the company have entered into a nonexclusive license agreement with Invitrogen Corporation, whereby Invitrogen has licensed from Ryogen the patent directed to the clinic
CogState has announced that it has been issued a patent from the Unites States Patent & Trade Mark Office (US patent no. 7,163,513) for the key technology platform used in its computer-based tests
Acusphere, Inc. announced today the issuance of U.S. Patent No. 7,160,557 B2, entitled "Matrices Formed of Polymer and Hydrophobic Compounds for Use in Drug Delivery." The patent covers the s
Nanion Technologies GmbH, a supplier of automated, parallel patch-clamp systems based in Munich, Germany, has announced that they would appeal the decision of the European Patent Office (EPO) to uphold t
Heska Corporation has announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liqu
GSK, the world's second-largest drug maker and the largest manufacturer of HIV/AIDS drugs currently controls over 40 percent of the worldwide market for HIV/AIDS drugs.
"On October 8, 2001 - more than two & a half years ago - GSK granted its first ever voluntary license to Aspen Pharmacare in South Africa to make generic GSK ARVs," said Michael Weinstein, AIDS Healthcare Foundation President. "Since then, not one pill has been produced in the only place on the planet that GSK has granted such voluntary licenses. GSK: your voluntary licensing is a scam."
In a related development, GlaxoSmithKline announced on July 1st - one week before the opening of this year's AIDS conference - that it has also now issued a voluntary license to South Africa's Thembalami Pharmaceuticals to produce generic versions of two of GSK's antiretroviral drugs, Reuters reports (Reuters, 6/29). Under the agreement, Thembalami - which is a joint venture between Adcock Ingram and India's Ranbaxy Laboratories -- will be allowed to produce generic versions of lamivudine and zidovudine, as well as a pill that combines the two drugs, South Africa's Business Day reports (Kahn, Business Day, 6/30).
"In a headline and in a press release, Glaxo's voluntary licensing of the patents for its AIDS drugs looks good," said Michael Weinstein, President of AIDS Healthcare Foundation. "Unfortunately, that's all these agreement seems to be - a headline and a press release. We have several questions on Glaxo's voluntary licensing agreement: Why is it taking so long to produce any of these drugs? This first agreement was signed more than two years ago, and why may Aspen only sell the drugs to the South African government? We are protesting today to ask GSK for answers and action on these questions."
http://www.aidshealth.org